AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 31 min read$ILMN

Davies Scott M sold $123K of ILMN

Davies Scott M (Chief Legal Officer) sold 615 shares of ILLUMINA, INC. (ILMN) at $200.00 ($0.12M total) on 2026-07-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Scott M
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure adds transparency on insider activity but does not introduce new company-specific fundamentals, guidance, or regulatory/product developments.

02

Market read

Traders may briefly factor in insider selling sentiment, but 10b5-1 plans typically reduce the signal value.

03

What to watch

The sale size is modest (615 shares) and the article provides no context on total holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, transaction dated 2026-07-30

Background

The article is a SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina Form 4 shows Chief Legal Officer Scott Davies sold 615 shares at $200 on 2026-07-30 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to intraday sentiment rather than a sustained repricing.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying new operational or financial disclosure.

Market effects

Sector

No clear read-through to biotech/healthcare tools demand or competitive dynamics from a small, planned insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with internal views on valuation or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • issuer
    Illumina, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Davies Scott M

    Chief Legal Officer who executed an open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 4
$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

fool.com6 min
JUL 31
$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

fool.com6 min
JUL 30
$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

financialcontent.com6 min
JUL 30
$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.

SEC EDGAR 8-K3 min